Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

AstraZeneca will acquire LogicBio

by Shi En Kim
October 8, 2022 | A version of this story appeared in Volume 100, Issue 36

 

Alexion, a rare disease–focused group within AstraZeneca, will acquire the genomic medicine company LogicBio Therapeutics. Alexion says it is interested in LogicBio’s technology for delivering and inserting genes using adeno-associated viruses to address rare genetic diseases. Alexion is paying $2.07 per share, or about $70 million—well over LogicBio’s share price of less than 50 cents before the deal was announced.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.